The efficacy of Tazemetostat was also evaluated in BRCA‐1 associated protein 1 (BAP1) inactivated cancers as preclinical data suggest that BAP1 inactivation leads to enhanced EZH2 expression associated with pronounced sensitivity to EZH2 inibition.31 Here, EZH2 is linked to cancer.